Mode
Text Size
Log in / Sign up
Phase 2 N=19 Treatment

Topical Antibiotics in Chronic Rhinosinusitis

Chronic Rhinosinusitis (Diagnosis)

Enrolled (actual)
19
Serious AEs
0.0%
Results posted
Apr 2022
Primary outcome: Primary: Subjects Who Developed Antibiotic Resistance Organisms — 0; 0; 1; 0 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Mupirocin (Drug); Tobramycin (Drug); Levofloxacin (Drug); Vancomycin (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Mayo Clinic
Primary completion
Feb 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Subjects Who Developed Antibiotic Resistance Organisms
0; 0; 1; 0
SECONDARY
Change in Patient Symptoms as Measured by the Sino-Nasal Outcomes Test (SNOT-22) Survey
-18; 14; -25.5; -11
SECONDARY
Change in Patient Physical Exam as Measured by the Lund-Kennedy Endoscopic Exam Scores.
-5.3; -3; -2.4; 0

Summary

Researchers are trying to find out if patients develop antibiotic resistant organisms after the use of topical antibiotics in the treatment of chronic rhinosinusitis.

Eligibility Criteria

Inclusion Criteria

  • Male or female, between 18-80 years old, diagnosed with chronic rhinosinusitis who have undergone previous functional endoscopic sinus surgery including at minimum maxillary antrostomy and anterior ethmoidectomy
  • Active mucopurulence on endoscopic examination with corresponding culture demonstrating pathogenic bacterial growth
  • Completion of written informed consent
  • No prior enrollment into this study
  • Refractory to maximal medical therapy

Exclusion Criteria

  • Patient has not had prior endoscopic sinus surgery consisting of at minimum maxillary antrostomy and anterior ethmoidectomy
  • Patient is currently being treated with oral antibiotics
  • Patient has been treated with oral or topical antibiotics within the past 14 days
  • Participation in an investigational drug study simultaneously with participation in this study
  • Concurrent use of oral steroids
  • Allergy to Tobramycin, Mupirocin, Gentamicin and Levofloxacin
  • Known to currently be pregnant
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03673956). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search